1kit (10Vial) .
| Di tin dɛn we yu kin gɛt: | |
|---|---|
| Ɔmɔs: | |
▎ Wetin na Krɔstɛm?
Kristagen na sεntetik pεptida-bεys bayolojikal mכdulet we fכs kכmכp fכ prolin, glutamik asid, εn aspartik asid. di kכr wok we i de du na fכ εnhans di bכdi in imyun rεspכns εn strεs rεsistεns bay we i de rεgεl di imyun sistεm fכ wok.
▎ we Krystagen de mek Di Strukchɔ
Sos: PepDraw we dɛn pul am |
Mɔlikul Fɔmula: C 14H 11N 3O8 Molikul Weyt:359.34g/mol |
▎ fɔ Ovagen Risach
Wetin na di risach bakgrɔn fɔ Crystagen?
di risεch bakgrכn fכ Crystagen fכs kכmכt frכm dip invεstigeshכn dεm pan imyun sistεm rεguleshכn εn εj-rεlatεd bayolojikal prכsεs dεm. we di ej de ol, di bεlε fכ di protin sεntesis εn fכ wok insay di bכdi de disrupt, we de mek difrεn sik dεm bigin. as sכt chen pεptida bayo-mכdulεta, di sikεns we di Crystagen de kכmכp fכ glutamik asid (Glu), aspartik asid (Asp), εn prolin (Pro)—de aktibכt jin εksprεshכn bay we i de kכmplimεntli biεn to spεsifi k DNA sayt dεm. dis de mek di protin sεntez, we de mek di fysiolojikal fכnshכn dεm sכstayn. dis mεkanism de gi wan tiori fכwndeshכn fכ delay ol εn εnhans imyun fכnshכn.
Wetin na di we aw Crystagen de wok?
Aktibכshכn fכ di B sεl dεm na di imyun sistεm
dayrekt aktibכshכn fכ B sεl dεm: Kristכjen de aktibכt B sεl dεm insay di imyun sistεm. di B sεl dεm fכs prodyuz antibodi dεm εn de tek pat pan di humoral imyun rεspכns dεm. we di patogen dεm invayd di bכdi, di B sεl dεm de no di antijen dεm εn de bi aktibכt tru wan siriכs signal path dεm. afta dat dεn de difrεnt to plasma sεl dεm we de kכl spεshal antibodi dεm fכ pul di patogens dεm. kristal kin aktibכt B sεl dεm bay we i de biεn spεsifi k rεsεpכta dεm na dεn sεf, we de trigεr intasεlulyar signal path dεm. dis de mek di B sεl dεm ebul fכ no di antijen dεm εn fכ bigin di imyun rεspכns dεm [1] ..
Wetin na di aplikeshɔn dɛn fɔ Crystagen?
insay imyun mכduleshכn, Crystagen de bכku bכku wan εnhans di bכdi in imyun fכnshכn, we de mek i bεnεfit fכ trit difrεn sik dεm we de kכl imyun. Dɛn kin yuz am fɔ trit akyu ɔ krɛse inflamɛns, lɛk infɛkshɔn na di say we yu de blo (lɛk farinjayt, brɔnkayt, saynayz, nyumonia, ɛn ɔda tin dɛn), infɛkshɔn na di urinary trakt (lɛk sistayt, paylɔnefrayt), prɔstataytis, ɛn adnɛksitis. Kristagen de sho bak fayn ifekt dεm fכ trit כtoimyun sik dεm εn sistεmik kכnektiv tisu dizכrd dεm, we de gi nyu tεrapi opshכn fכ dεn kכndyushכn dεm ya.
Insay di postɔpareshɔn ɛn rihabiliteshɔn sɛtin, dɛn kin yuz Crystagen we dɛn de du difrɛn ɔpreshɔn bifo ɛn afta ɔpreshɔn fɔ ɛp di sikman dɛn fɔ mek dɛn bɔdi gɛt trɛnk bak ɛn di imyun fɔ wok bak. Fɔ di sik pipul dɛm we de wɛl frɔm hat atak ɔ strok, Crystagen de ɛp fɔ mek dɛn bɔdi wɛl ɛn i de ridyus di prɔblɛm dɛn we kin apin. Di we aw dɛn de yuz am pan ol pipul dɛn ɛn pipul dɛn we gɛt imyun kɔmprɔmis de gɛt bɔku atɛnshɔn bak. I de ɛp fɔ mek di ol pipul dɛn imyun wok fayn ɛn i de ɛp fɔ mek di imyun dεn dεn dεn dεklin bikɔs ɔf di ej. Fɔ di sik pipul dɛm we dɛn afɛkt wit bad bad tin dɛm lɛk infɛkshɔn, redyushɔn, kemotɛrapi, imɔshɔnal strɛs, tin dɛm we de apin na di envayrɔmɛnt, klaymat kɔndishɔn, endemik sik dɛm, ɛn ayɔniz redyushɔn, Krɔstɛm de du fayn fayn rigyuletɔri ifɛkt dɛm, we de ɛp di bɔdi in sik rɛsistɛns.
Kristagen de sho bak se i kin ebul fɔ mek di tɔŋ nɔ apin. bay we i de mכdulet di imyun sistεm fכ wok, i kin εp fכ ridyus di risk fכ di tכmכro divεlכpmεnt. Apat frɔm dat, dɛn kin yuz Crystagen fɔ trit pɔyzin we nɔ de dɔn, we de ɛp fɔ mek di wan dɛn we gɛt pɔyzin wɛl.
Dɔn
as sεntetik pεptida-bεys bayolojikal mכdulet, Crystagen de sho imyunmodulatory ifekt dεm, we de εnhans imyun fכnshכn εn impruv imyun dεfisiεns stet dεm we difrεn fכs tin dεm kכz. I de sho se i ebul fɔ trit akyu ɔ kronik inflamɛns, vayral infɛkshɔn, fɔ wɛl afta dɛn dɔn ɔpreshɔn, ɛn di imyun dɛklin we gɛt fɔ du wit di ej. Kristagen de du fayn fayn tin dɛn bak fɔ mek dɛn nɔ gɛt tumor ɛn fɔ trit pɔyzin we nɔ de dɔn.
Bɔt di pɔsin we rayt di buk
Di tin dɛn we wi dɔn tɔk bɔt, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.
Sayɛns Jɔnal Author
Chervyakova NA na risachman na di Saint-Petersburg Institute of Bioregulation and Gerontology, Russia, we de pe atɛnshɔn pan mɔlikul aspek dɛm fɔ imyumoduleshɔn ɛn chenj dɛm we gɛt fɔ du wit di ej na di imyun wok. Chervyakova NA de list insay di rεfrεns fכ saytεshכn [1].
▎ Saytayshɔn dɛn we gɛt fɔ du wit dis
[1] Сhervyakova N. A., Linkova N. S., Chalisova N. I., Kɔnsɛvaya E. A., Trofimova S. V., Khavinsɔn V. K. [Mכlikul aspεkt dεm fכ imyunprotεktiv aktvכti fכ pεptida dεm na di splin di tεm we di prכsεs de ol]. Advans in Jɛrɔntɔlɔji 2014; 27 (1): 224-228.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgicmd=Ritriv&db=pubmed&dopt=Abstrakt&list_uids=28976144&kwɛstyɔn_hl=1.
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.